This is one of the first cases in which a manufacturer of generic drugs claimed damages for having been prevented from accessing the market. This case was settled after more than three weeks at trial. The settlement remains confidential. Several lawyers from the firm worked on this file. Mr. Lefebvre’s role consisted in managing the various witnesses to be examined, and especially cross-examination. In the months preceding the trial, he examined witnesses in India for several days on highly technical issues pertaining to the production of pharmaceutical products.